![Deshpande Wiesler Deshpande Wiesler](/sites/default/files/2024-08/Website_OhneLogo.jpg)
August 30, 2024
Boehringer Ingelheim announces appointments Board of Managing Directors
![Boehringer_Workplace_Lab_Research-01 Boehringer_Workplace_Lab_Research-01](/sites/default/files/2024-08/Boehringer_Workplace_Lab_Research-01_RGB_010.jpg)
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
![Boehringer Ingelheim acquires Nerio Therapeutics in the lab](/sites/default/files/2024-07/Nerio.png)
July 29, 2024
Boehringer Ingelheim acquires Nerio Therapeutics
![CHMP-positive-opinion-SPEVIGO CHMP-positive-opinion-SPEVIGO](/sites/default/files/2024-07/CHMP-positive-opinion-SPEVIGO.jpg)
July 29, 2024
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
![Boehringer_Workplace_Lab_Research Boehringer_Workplace_Lab_Research](/sites/default/files/2024-07/Boehringer_Workplace_Lab_Research-01_CMYK_001%20resized.png)
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
![Ingelheim biomass plant inauguration cropped Ingelheim biomass plant inauguration cropped](/sites/default/files/2024-07/0O9A7814Bearb_cropped.jpg)
July 08, 2024
Boehringer Ingelheim produces its own green energy
![Boehringer Ingelheim advances SIRP immune-oncology program Pipettes with violet fluid](/sites/default/files/2024-07/PR_OSE2.jpg)
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
![Phase 1 start for novel triple agonist obesity treatment Woman working in the lab on a laptop](/sites/default/files/2024-07/PR_Grupa.jpg)
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
![3-Lab-techs 3-Lab-techs](/sites/default/files/2024-06/3-Lab-techs-v2%20%281%29.png)
June 07, 2024
Survodutide shows breakthrough improvement in liver fibrosis
![Boehringer Ingelheim Economist Impact Boehringer Ingelheim Economist Impact](/sites/default/files/2024-05/Boehringer_Lifestyle_SocialLife_MeetingFriends-01_CMYK_018.png)
May 28, 2024
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
![Man in the lab Man working in the lab](/sites/default/files/2024-05/PR_OSE.jpg)
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
![Sheep with bell are looking at camera Sheep with bell are looking at camera](/sites/default/files/2024-05/Bultavo%20press%20release.jpg)
May 13, 2024
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3)
![Hornbill Press Release Woman in the lab](/sites/default/files/2024-05/HornbillPR.jpg)
May 06, 2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
![Veterinarian treats dog, chicken is being held in barn Veterinarian treats dog, chicken is being held in barn](/sites/default/files/2024-04/Veterinarian%20treats%20dog%2C%20chicken%20is%20being%20held%20in%20barn.jpg)
April 25, 2024
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated
![boehringer_biopharmaceutical production_Biberach boehringer_biopharmaceutical production_Biberach](/sites/default/files/2024-04/boehringer_biopharmaceutical%20production_Biberach%20resized.jpg)
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 09, 2024
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
![EMPA EMPA](/sites/default/files/2024-04/EMPA%20image.png)
April 06, 2024
Results announced from EMPACT-MI phase III trial
![Boehringer Workplace Lab Research Boehringer Workplace Lab Research](/sites/default/files/2024-03/Boehringer_Workplace_Lab_Research-01_RGB_003%20%281%29.jpg)
March 19, 2024
SPEVIGO® approved for expanded indications in China and the US
![Boehringer_Lifestyle_SocialLife_MeetingFriends Two persons talking](/sites/default/files/2024-03/Boehringer_Lifestyle_SocialLife_MeetingFriends-01_RGB_008.jpg)
March 11, 2024
New partnership to develop schizophrenia treatments
![MASH MASH](/sites/default/files/2024-03/MASH_klein_1_0.png)
February 26, 2024
Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
![Girl with horse in front of a camera](/sites/default/files/2024-02/Sleip_Partnership_website.png)
February 19, 2024
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
![doctor pointing on spine](/sites/default/files/2024-02/CBmed.jpg)
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
![Employee in learning environment](/sites/default/files/2024-01/Untitled%20design%20%281%29.png)
January 18, 2024
Global Top Employer 2024 certification reflects Boehringer Ingelheim’s impactful people development
![Koropi groundbreaking](/sites/default/files/2024-01/Koropi%20groundbreaking.jpg)
January 11, 2024
Boehringer expands production site in Greece for new medicine
![Man with cat](/sites/default/files/2024-01/SENVELGO%20wins%20Best%20New%20Product%20for%20Companion%20Animals%20award%E2%80%8B.png)
January 10, 2024
SENVELGO® wins Best New Product for Companion Animals award
![Scientists/doctors looking on a tablet](/sites/default/files/2024-01/ADVANCE.jpg)
January 09, 2024
New study paves the way for liver cirrhosis treatments
![Discussion of doctors and caregivers](/sites/default/files/2024-01/JPM_summary.jpg)
January 09, 2024
Kicking off 2024 with five new R&D partnerships
![Kyowa](/sites/default/files/2024-01/Malin_Kyowa_1.jpg)
January 05, 2024
Boehringer Ingelheim licenses a new compound as part of its commitment to people living with fibro-inflammatory diseases from Kyowa Kirin
![Partnership 3T Bio Partnership 3T Bio](/sites/default/files/2024-01/Malin.png)
January 04, 2024
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies
![Scientists in the lab](/sites/default/files/2024-01/PR_Ribo.png)
January 03, 2024
Partnership for new liver disease treatments with Ribo
![Huebler_Schmelmer Huebler_Schmelmer](/sites/default/files/2023-12/Huebler_Schmelmer.jpg)
December 18, 2023
Boehringer Ingelheim announces appointments Board of Managing Directors
![Doctors in a discussion](/sites/default/files/2023-11/IBM%20PRess.jpg)
November 28, 2023
Partnership with IBM to accelerate new antibody therapies
![Diabetic cat with owner](/sites/default/files/2023-11/Diabetic%20cat%20with%20owner.png)
November 23, 2023
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
![Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss](/sites/default/files/2023-11/BI_Workplace_Lab_Discussion-01_RGB_001%20%281%29.jpg)
November 22, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
![Asi+empa image.jpg](/sites/default/files/2023-11/Asi%2Bempa%20image.jpg)
November 03, 2023
Boehringer Ingelheim achieves major milestone in chronic kidney disease
![Life forward release 1](/sites/default/files/2023-10/MicrosoftTeams-image%20%2810%29.png)
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
![Prix Galien 2023.jpeg](/sites/default/files/2023-10/Prix%20Galien%202023.jpeg)
October 30, 2023
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
![Phase III trials_image.png](/sites/default/files/2023-10/Phase%20III%20trials_image.png)
October 05, 2023
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
![Woman and Man in Computer room](/sites/default/files/2023-10/AdobeStock_160945102.jpeg)
October 02, 2023
Partnership with Precision Health Research, Singapore
![Eye in detail](/sites/default/files/2023-10/CRD_PR.jpg)
October 02, 2023
Phase 1 start of treatment for Geographic Atrophy patients
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
![KMP_tree_ClimateSeed_Ⓒ Permian Global 1440 x 810 plus Copyright 460kb.jpg](/sites/default/files/2023-09/KMP_tree_ClimateSeed_%E2%92%B8%20Permian%20Global%201440%20x%20810%20plus%20Copyright%20460kb.jpg)
September 14, 2023
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
![Man with cattle herd](/sites/default/files/2023-08/Credits%20%40GALVmed%20Karel%20Prinsloo.jpg)
September 05, 2023
New partnership working on solutions to combat African animal trypanosomiasis
![Obesity release.png](/sites/default/files/2023-08/Obesity%20release.png)
August 17, 2023
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
![Man with cat on sofa](/sites/default/files/2023-08/FDA%20Approval%20Senvelgo.jpg)
August 14, 2023
Boehringer Ingelheim receives FDA approval for SENVELGO®: the first oral liquid medication for diabetes in cats
![HY 2023 press release image](/sites/default/files/2023-07/HY%202023%20press%20release%20image%20resized.jpg)
August 01, 2023
First half of 2023: strong growth and expansion in key therapy areas
July 28, 2023
FRONTLINE® wins Brand of the Year Award for the third time in a row
![Kidney Diseases Kidney Diseases](/sites/default/files/2023-07/hands%20%26%20kidney%20image_1280x720_v01%5B37%5D.jpg)
July 25, 2023
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
![Female veterinarian with dog in practise, woman and kid standing in background](/sites/default/files/2023-07/NexGard%20PLUS%2016x9.png)
July 20, 2023
Boehringer Ingelheim receives FDA approval for NexGard® PLUS: a beef-flavored soft chew that protects dogs from internal and external parasites
![A person touching a scientific data visualization](/sites/default/files/2023-07/MicrosoftTeams-image%20%286%29.png)
July 04, 2023
Spesolimab prevents GPP flares
![Scientist with tablet stock image](/sites/default/files/2023-06/Scientist%20with%20tablet.jpg)
June 23, 2023
Phase II trial data shows nearly 19% weight loss in people with overweight or obesity
![230622_CKD_CHMP_WebsiteCard_1440x810px.jpg](/sites/default/files/2023-06/230622_CKD_CHMP_WebsiteCard_1440x810px.jpg)
June 23, 2023
Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU
![Phase II trial results in people living with obesity or overweight](/sites/default/files/2023-05/shutterstock_1901403778.jpg%201440%20%C3%97%20810.jpg)
May 10, 2023
Phase II trial results in people living with obesity or overweight
![colorful picture](/sites/default/files/2023-05/FibroticDisease.jpg)
May 09, 2023
IL-11 inhibitor antibody clinical development launched
![SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares Finger pointing at a digital tick box](/sites/default/files/2023-05/Spesolimab%20Breakthrough%20Designation%20Press%20Release%20Image.jpg)
May 02, 2023
Breakthrough Designation granted in US and China
![Dreyer_vonBaumbach_Scholz Dreyer_vonBaumbach_Scholz](/sites/default/files/2023-05/MicrosoftTeams-image%20%283%29.png)
May 02, 2023
Boehringer and German Chancellor Olaf Scholz lay the foundation stone for EUR 285 million innovation center
![Einweihung BDC](/sites/default/files/2023-04/Einweihung%20BDC%2024.April%20resized.png)
April 24, 2023
Boehringer inaugurates largest European development centre for biotechnology
![ARPC press release](/sites/default/files/2023-03/069_%C2%A9%202020%2C%20Peter%20Ginter%20-%20inspection%20shovel%20dryer%20fro%20website%20.jpg)
March 29, 2023
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
![People standing in a circle in rural Africa](/sites/default/files/2023-02/LastMile%20Press%20Release%20Thumbnail.jpg)
March 02, 2023
LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
![A doctor speaks to a patient about results of medical checks whilst sat in a general practice A female doctor speaks to a male patient about results of medical checks whilst sat in a general practice](/sites/default/files/2023-01/Effisayil%202%20-GettyImages-1212860058%20resize.jpg)
January 30, 2023
Spesolimab meets key endpoint for GPP flare prevention
![Empa_Kidney](/sites/default/files/2023-01/shutterstock__Klein.jpg)
January 24, 2023
FDA accepts application for new CKD treatment
![Top Employer 2023 Top Employer 2023](/sites/default/files/2023-01/BI_1570.jpg)
January 17, 2023
Global Top Employer 2023
![monecules](/sites/default/files/2023-01/Teaser_3t.jpg)
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
![](/sites/default/files/Images/apc_2016_bic.jpg)
December 20, 2022
Boehringer Ingelheim announces appointments to Board of Managing Directors
![woman with mobilephone](/sites/default/files/2022-12/ClickTxTeaser.png)
December 19, 2022
New digital Tx collab with Click
![EC grants marketing authorization for spesolimab](/sites/default/files/2022-12/786212587-009_400x400px_cc01.jpg)
December 13, 2022
EC grants conditional marketing authorization for spesolimab
![New positive data in Phase III type 2 diabetes trial](/sites/default/files/2022-12/shutterstock_1021932094.jpg)
December 07, 2022
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
![EMPA-KIDNEY trial meets primary endpoint EMPA-KIDNEY trial meets primary endpoint](/sites/default/files/2022-11/BI%20Kidney%20image_1920x1080px_0.jpg)
November 04, 2022
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
![Tree shaped as lungs with the press release title On the left side of the image is the label which reads #Press’. Under the label is the text which reads First Patient enrolled in FIBRONEER-IPF Phase III trial. The right side of the image shows a tree shaped as lungs](/sites/default/files/2022-10/BI.com%20Post%20Release.jpg)
October 26, 2022
FIBRONEER™ Phase III program initiated in over 40 countries
![AI&Data Science Fellowship Tuebingen](/sites/default/files/2022-10/Tue%20Fellowship%20prog.jpg)
October 20, 2022
AI and Data Science Fellowship with University of Tuebingen
![Scientific laboratory staff member wearing a lab coat looks into a microscope Female scientific laboratory staff member wearing a lab coat uses a microscope by staring into it](/sites/default/files/2022-10/CHMP%20Upload%20form%20image_1440x810_CC02.jpg)
October 14, 2022
CHMP recommends conditional approval for first GPP treatment
![The 2022 PRRS Award Winners Collage of four individual headshots, three men, one woman](/sites/default/files/2022-09/PRRS%20Awards%202022%20Thumbnail%20%282%29.png)
October 10, 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
![Cowtribe in action](/sites/default/files/2022-09/20200823_112854.jpg)
October 05, 2022
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
![Birth of a calf](/sites/default/files/2022-09/335A4008.jpg)
September 06, 2022
Boehringer Ingelheim launches Fencovis®, a new vaccine to prevent calf diarrhea
![New Phase III data in children living with ILD New Phase III data in children living with ILD](/sites/default/files/2022-09/InPedILD_ERS_press_release.jpg)
September 05, 2022
New data for nintedanib in children with fibrosing interstitial lung disease
![Person holds scientific breakthrough in their hands Businessman using digital x-ray human body scan interface 3D rendering](/sites/default/files/2022-09/Image-for-FDA-Press-release_1440x810px.jpg)
September 02, 2022
First approval for SPEVIGO® to treat GPP flares
![People working in a lab](/sites/default/files/2022-08/16%209%20size%20People%20working%20in%20a%20lab.jpg)
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
![Small group of female laboratory assistants checking blood, using microscope and doing tests](/sites/default/files/2022-06/16%209%20size%20Small%20group%20of%20female%20laboratory%20assistants%20checking%20blood%2C%20using%20microscope%20and%20doing%20tests.jpg)
July 06, 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
![T-cell 1440_810.png](/sites/default/files/2022-06/T-cell%201440_810.png)
June 14, 2022
Option to Acquire Trutino Biosciences
![Vet examining dog Vet examining dog](/sites/default/files/2022-05/China_MG_4648.jpg)
June 14, 2022
Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology
![Medical worker showing a heart](/sites/default/files/2022-06/EMPRISE_website_card_image_16_9.jpg)
June 06, 2022
Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
![A*Star](/sites/default/files/2022-06/thumbnail.jpg)
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
![Learn about our latest investigational treatment that slowed lung function decline in people with IPF Visual representation of human lungs](/sites/default/files/2022-05/786212706-002_BI_PF_ATS_Press-Release_Social_1920x1080_CC03_image-only_0.jpg)
May 15, 2022
Investigational treatment slowed lung function decline in IPF
![Man injects piglet with vaccines that have been mixed in TwistPak](/sites/default/files/2022-05/TwistPak%20hero%20image.jpg)
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
![AI machine deep learning.jpg](/sites/default/files/2022-05/AI%20machine%20deep%20learning.jpg)
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
![A woman rides a horse A woman rides a horse](/sites/default/files/2022-04/RenuTend%20visual.png)
April 21, 2022
Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
![048_© 2020, Peter Ginter - final adjustments at the “pipe crossover”](/sites/default/files/2022-04/048_%C2%A9%202020%2C%20Peter%20Ginter%20-%20final%20adjustments%20at%20the%20%E2%80%9Cpipe%20crossover%E2%80%9D%20resized.png)
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
![data](/sites/default/files/2022-03/Data.jpg)
March 29, 2022
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
![Urban girl standing out from the crowd at a city street.](/sites/default/files/2022-03/AAD%20press%20release%20supporting%20image_resized.png)
March 28, 2022
New spesolimab data show significant improvement in GPP flares
![Cows in stable](/sites/default/files/2022-03/_15A3705_0.jpg)
March 22, 2022
Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being
![EMPA-KIDNEY](/sites/default/files/2022-03/220316_EMPA-KIDNEY_Early-Stop_0.jpg)
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
![EMA_PressRelease](/sites/default/files/2022-03/EMA_website_teaser_card_16_9.jpg)
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
![Patient and Doctor talking to each other. You can only see their hands](/sites/default/files/2022-03/EMPULSE_Image_2_Doctor_Patient.jpg)
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
![Data digital](/sites/default/files/2022-02/400x400smallformat_Digital1.jpg)
March 01, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
![Hands holding a heart](/sites/default/files/2022-02/FDA_website_teaser_card_16_9.jpg)
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
![White lung shown on mint background](/sites/default/files/2022-02/786212575-009_BI_IPF_FDA%20Asset_1440X810_CC01-01.jpg)
February 24, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
![Cattle herd](/sites/default/files/2022-01/black%20cow%202.jpg)
February 09, 2022
New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows
![Heardbeat in context of heart failure](/sites/default/files/2022-02/CHMP_website_teaser_card_16_9.jpg)
January 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
![Top Employer](/sites/default/files/2022-01/Mediapool_TopEmployer2022%20%281%29.jpg)
January 20, 2022
Award: Boehringer Ingelheim is Global Top Employer 2022
![Immunology](/sites/default/files/2022-01/400x400smallformat_Immuno.jpg)
January 18, 2022
Collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
![GPP_Press_Release](/sites/default/files/2021-12/Supporting%20press%20release%20image.png)
December 23, 2021
Spesolimab Phase II data
![FDA Press Release](/sites/default/files/2021-12/211213%20FDA%20Press%20Release%20Image_1440x810_72dpi_cc01.jpg)
December 15, 2021
U.S. FDA grants priority review for spesolimab in GPP
![BISE_Bungoma_County.jpg](/sites/default/files/2021-12/BISE_Bungoma_County.jpg)
November 11, 2021
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
![Making-more-health-together-2021 Making-more-health-together-2021](/sites/default/files/2023-03/MMHT_visual.jpg)
November 11, 2021
Making More Health Together 2021: Creating sustainable health solutions for 50 million people in vulnerable communities
![](/sites/default/files/Images/press-release-holding-image02.jpg)
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
![commitments to sustainable development commitments to sustainable development](/sites/default/files/2023-03/More%20Potential_Picture%20for%20Tweet.jpg)
November 03, 2021
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
![environmental sustainability commitments environmental sustainability commitments](/sites/default/files/2023-03/MoreGreenCard_400x400px.jpeg)
November 01, 2021
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
![](/sites/default/files/Images/press-release-holding-image03.jpg)
October 29, 2021